Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2007

View Archived Issues

Effects of 2R,4R-APDC reduced when given after seizure onset

Novel treatments for inflammatory disorders claimed in recent patent literature

Neuropeptide Y a therapeutic target for obesity

COG-1410 therapeutic in models of traumatic brain injury

Novartis highlights performance in first half of 2007

Acadia receives milestone payment for drug candidate for glaucoma

Update on Cook Medical's phase II trial of drug-coated stent

Affymax begins phase III trials of Hematide

Gruenenthal and Aventis sign licensing agreement for trimegestone

Novel agents for respiratory disorders claimed in recent Novartis, Novartis Pharma and Pfizer patent

Recent Astellas patent discloses novel treatment option for urological disorders

CS-917 fails to significantly lower placebo-adjusted HbA1c level in phase IIb study

Treatment begins in phase III trial of Litx for metastatic colorectal cancer

Orchestra Therapeutics discontinues HIV vaccine development program

ACZ-885 begins phase III for Muckle Wells syndrome

Pharmacopeia advances first therapeutic program with GSK

Banyu to change name to Merck-Banyu

Delay in data from phase III extension study of safinamide in early Parkinson's

Further encouraging phase II findings for ralfinamide in neuropathic pain

CDC adopts RotaTeq and Gardasil vaccination program

Update on Can-Fite's phase IIb study of methotrexate for RA

Positive results from Durect's phase IIb trial of Posidur for hernia repair pain

Avicena to begin confirmatory phase III trial of AL-02 for ALS

Seretide approved in Europe for broader COPD population

NDA submission for TMC-125

Cervarix recommended for approval in Europe and launched in Australia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...